Omega-3 Fish Oil

Omega-3 fish oil is the most extensively studied supplement in the history of medicine — and the gap between public perception and trial evidence is wider here than almost anywhere else. For decades, the narrative was simple: fish oil prevents heart attacks. The reality, shaped by three landmark trials, is more nuanced and more honest.

The mechanism is well-established. EPA and DHA are long-chain omega-3 fatty acids that displace arachidonic acid in cell membranes, shifting eicosanoid production toward less inflammatory mediators. They reduce hepatic VLDL synthesis, lower triglycerides by 20-30% at adequate doses, and produce specialized pro-resolving lipid mediators (resolvins, protectins, maresins) that actively resolve inflammation. DHA is preferentially incorporated into neural tissue and is essential for retinal and cortical development.

The trial evidence tells a stratified story. The GISSI-Prevenzione trial (1999) remains foundational: 11,324 post-myocardial infarction patients given 1g/day of n-3 PUFA showed a 14% reduction in all-cause mortality and a 17% reduction in cardiovascular death, with much of the benefit attributable to a 45% reduction in sudden cardiac death. This established omega-3s as standard adjunctive care in secondary prevention — on top of aspirin, statins, beta-blockers, and ACE inhibitors.

Then came VITAL (2019), the largest primary prevention trial to date: 25,871 healthy older adults randomized to 1g/day omega-3 or placebo for a median 5.3 years. The primary endpoint — major cardiovascular events — showed no significant difference (HR 0.92, p=0.24). No cancer benefit either. The trial was not a failure; it was a precision instrument that showed omega-3s do not meaningfully prevent first heart attacks in already well-nourished populations. A subgroup signal emerged: participants with low baseline fish intake (<1.5 servings/week) showed a 19% reduction in major CV events, and total myocardial infarction was reduced by 28% overall.

The REDUCE-IT trial (2019) added a critical distinction. This was not generic fish oil — it was prescription icosapent ethyl (pure EPA, 4g/day) in 8,179 statin-treated patients with elevated triglycerides. The result was a 25% reduction in major cardiovascular events, including cardiovascular death. This is the strongest cardiovascular evidence for any omega-3 formulation, but it applies to a specific high-risk population at a dose no OTC supplement provides.

The honest framing: if you eat fatty fish regularly, adding OTC fish oil is unlikely to reduce your cardiovascular risk. If you are post-MI, omega-3s have mortality data supporting their use. If you have high triglycerides on statins, prescription EPA is evidence-based and distinct from anything on the supplement shelf. For general anti-inflammatory or mood support, the evidence is suggestive but not definitive.

Practical guidance: 1-2g/day combined EPA+DHA for general wellness; 2-4g/day for triglyceride reduction. Take with meals to enhance absorption and reduce fishy reflux. If you are on warfarin, aspirin, or any anticoagulant, discuss with your physician before starting. Choose molecularly distilled products verified by third-party testing (USP, NSF, IFOS) to minimize oxidation and contaminant risk.